A Comparison of the Clinical Outcomes of Haploidentical Transplantation and Other Graft Sources in Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis

Owattanapanich, Weerapat; Leelakanok, Nattawut; Sanpakit, Kleebsabai; Buaboonnam, Jassada

doi:10.1016/j.clml.2021.09.024

Cited by 6 publications

(2 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several meta-ana ly ses have com pared haplo to other graft sources, includ ing CBT, as stem cell sources for allo ge neic transplan ta tion. 19 In 1 such meta-anal y sis recently reported by Owattanapanich et al com par ing haplo-SCT and CBT in patients with ALL in mostly reg is try-based stud ies, the pooled odds ratios of OS and LFS in the haplo-SCT and CBT groups were not sta tisti cally dif fer ent. Similarly, the NRM, RI, and aGVHD grade 2 to 4 out comes of the 2 groups did not sta tis ti cally dif fer.…”

Section: Haplo-sct Vs Cbt: Meta-anal Y Sismentioning

confidence: 89%

In 2022, which is preferred: haploidentical or cord transplant?

Nagler

Mohty

2022

Hematology

View full text Add to dashboard Cite

Allogeneic hematopoietic stem cell transplantation is the treatment of choice for high-risk hematological malignancies such as acute myeloid and lymphocytic leukemia, myelodysplastic syndrome, and myeloproliferative disorders. Alternative donor transplantation from either haploidentical (haplo-SCT) or cord blood donor (CBT) is an established therapeutic alternative for patients who need transplants but lack a human leukocyte antigen–matched donor. Although haplo-SCT (mainly non–T-cell-depleted haplo-SCT with posttransplant cyclophosphamide) is increasing while CBT is decreasing worldwide (Figure 1), recent developments in CBT, especially cord blood expansion and other strategies to improve engraftment and immune reconstitution post-CBT, make CBT still a valuable option. This article discusses the 2 options based on the currently available data, focusing on adults, and tries to give some clues to help the transplant physician choose a haploidentical vs a cord blood donor. Given the limited numbers of published or ongoing well-designed randomized controlled trials comparing haplo-SCT to CBT and the overall similar clinical results in the available, mostly registry-based, and single-center studies, with substantial heterogeneity and variability, the decision to perform haplo-SCT or CBT in a given patient depends not only on the patient, disease, and donor characteristics and donor availability (although most if not all patients should have in principle an alternative donor) but also on the transplant physician's discretion and, most importantly, the center's experience and preference and ongoing protocols and strategies.

show abstract

Section: Haplo-sct Vs Cbt: Meta-anal Y Sismentioning

confidence: 89%

In 2022, which is preferred: haploidentical or cord transplant?

Nagler

Mohty

2022

Hematology

View full text Add to dashboard Cite

show abstract

“…Intensive cytotoxic drug therapy, site-targeted radiotherapy, and HSCT have been the mainstays of treatment until the advent of immunotherapeutic regimens. Graft versus host disease is a common complication of HSCT [ 57 ]. Critical considerations include therapies for relapsed and refractory ALL, complete remission, and the role of immunotherapies [ 49 , 50 , 58 ].…”

Section: Reviewmentioning

confidence: 99%

A Review of Acute Lymphocytic Leukemia (ALL) in the Pediatric Population: Evaluating Current Trends and Changes in Guidelines in the Past Decade

Ekpa,

Akahara,

Anderson

et al. 2023

Cureus

View full text Add to dashboard Cite

Acute lymphocytic leukemia (ALL) is a commonly diagnosed cancer in children. Despite technological advancements to improve treatment and survival rates, there has been a steady increase in the incidence of ALL and treatment failures. This paper discusses the pathogenic interaction between genetic and environmental factors leading to childhood ALL. It evaluates the current treatment guidelines and notable obstacles leading to resistance, relapse, and treatment toxicities. The review evaluates a 10-year trend in the management guidelines of pediatric ALL through a systematic literature review of records from 2012 to 2023. Findings show that improvement in the five-year survival rates, notwithstanding rates of relapse and incurable diseases, is still high. Furthermore, several risk factors, including an interplay between genetic and environmental factors, are largely contributory to the outcome of ALL treatments and its overall incidence. Moreover, huge financial costs have remained a significant challenge in outcomes. There remains a need to provide individualized treatment plans, shared decision-making, and goals of care as parts of the management guidelines for the best possible outcomes. We expect that future advancements will increase overall survival rates and disease-free years.

show abstract

Haploidentical Hematopoietic Stem Cell Transplantation in India-Bridging the Gap

Mishra,

Naithani

2024

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

A Comparison of the Clinical Outcomes of Haploidentical Transplantation and Other Graft Sources in Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis

Cited by 6 publications

References 41 publications

In 2022, which is preferred: haploidentical or cord transplant?

In 2022, which is preferred: haploidentical or cord transplant?

A Review of Acute Lymphocytic Leukemia (ALL) in the Pediatric Population: Evaluating Current Trends and Changes in Guidelines in the Past Decade

Haploidentical Hematopoietic Stem Cell Transplantation in India-Bridging the Gap

Contact Info

Product

Resources

About